传承中医药经典,创新微循环发展——中国中药协会微循环用药专业委员会成立大会暨冠脉微循环研究新进展学术研讨会

2018-05-21 MedSci MedSci

中医药学作为传统医学的突出代表,它植根于中华文化的深厚土壤,惠及东方、影响世界,是全人类的共同财富。5月20日,由中国中药协会主办、上海和黄药业有限公司承办的中国中药协会微循环用药专业委员会(专委会)成立大会暨冠脉微循环研究新进展学术研讨会在上海如期召开。本次大会受到各医疗单位、科研单位、高等院校、中药企业的广泛响应和大力支持,中国科学院陈凯先院士、中国中药协会房书亭会长、国家中医药管理局政策法规

中医药学作为传统医学的突出代表,它植根于中华文化的深厚土壤,惠及东方、影响世界,是全人类的共同财富。5月20日,由中国中药协会主办、上海和黄药业有限公司承办的中国中药协会微循环用药专业委员会(专委会)成立大会暨冠脉微循环研究新进展学术研讨会在上海如期召开。本次大会受到各医疗单位、科研单位、高等院校、中药企业的广泛响应和大力支持,中国科学院陈凯先院士、中国中药协会房书亭会长、国家中医药管理局政策法规与监督司杨荣臣副司长、中国中药协会刘张林副会长、王桂华秘书长、上海药学会王龙兴理事长等200多名行业专家及企业代表参会;此外,本次大会进行了同步网络直播,共 17个省市约1200余人观看了此次盛会,共享这开放融合的大平台。

在微循环用药及治疗方面,中医药有着独特的优势,微循环用药研究将会为临床用药提供有力证据,进一步阐明中药作用机理,促进中医药产业的健康发展。在中国中药协会的大力指导和支持下,由上海中医药大学、海军军医大学附属长征医院、上海和黄药业牵头,联合国内知名医疗,科研,大学及中药企业等单位共同发起成立中国中药协会微循环用药专业委员会。专委会的成立,对推进我国中医药在微循环防治领域的研究方法与评价标准构建,完善微循环的中医药防治,推动微循环学术发展具有重要意义。


中国中药协会房书亭会长主持大会



中国中药协会微循环用药专业委员会名誉主任委员、中国科学院陈凯先院士致辞



中国中药协会微循环用药专业委员会主任委员、上海中医药大学王峥涛教授致辞


上海市药学会王龙兴理事长致辞


国家中医药管理局政策法规与监督司杨荣臣副司长致辞


中国中药协会微循环用药专业委员会荣誉主任委员颁证仪式

 
上海中医药大学王峥涛教授  海军军医大学附属长征医院梁春教授  上海和黄药业有限公司周俊杰先生

中国中药协会微循环用药专业委员会主任委员颁证仪式


中国中药协会微循环用药专业委员会顾问颁证仪式


中国中药协会微循环用药专业委员会授牌仪式

中国中药协会房书亭会长主持会议。中国科学院陈凯先院士、上海中医药大学王峥涛教授、上海市药学会王龙兴理事长、国家中医药管理局政策法规与监督司杨荣臣副司长等与会专家和特邀嘉宾在会上致辞。会议确定了专委会的机构组成,中国中药协会微循环用药专业委员会聘请中国中医科学院西苑医院陈可冀院士、中国科学院陈凯先院士、复旦大学附属中山医院葛均波院士、中国中药协会房书亭会长、复旦大学附属华山医院戴瑞鸿教授担任名誉主任委员;聘请复旦大学附属华山医院范维琥教授、海军军医大学附属长征医院吴宗贵教授担任专委会顾问。选举上海中医药大学王峥涛教授、海军军医大学附属长征医院梁春教授、上海和黄药业有限公司周俊杰总裁担任首届主任委员,同时选举行业重要专家及企业代表担任专委会副主任委员、常务委员及委员。 


中国中药协会微循环用药专业委员会顾问,复旦大学附属华山医院范维琥教授、海军军医大学附属长征医院吴宗贵教授主持专题学术会并点评


中国中药协会微循环用药专业委员会主任委员、海军军医大学附属长征医院梁春教授作学术报告


中国中药协会微循环用药专业委员会副主任委员、复旦大学附属华山医院施海明教授作学术报告


中国中药协会微循环用药专业委员会副主任委员、上海中医药大学创新中药研究院张建革教授作学术报告

学术环节以“冠脉微循环研究新进展”为主题,邀请国内著名的临床专家、药学专家、科研专家等莅临讲学,交流中医药在微循环防治领域的进展和基础研究方面取得的新成就,对该领域热点问题进行深入讨论和经验交流。中国科学院陈凯先院士分析当代医学发展的挑战和趋势,阐述中医药的机遇和使命。海军军医大学附属长征医院梁春教授分析冠脉微循环国内外研究进展,复旦大学附属华山医院施海明教授则阐述了中医药与冠脉微循环研究进展;上海中医药大学创新中药研究院张建革教授带来了关于基于巨噬细胞介导麝香保心丸促血管新生作用机制研究的报告,精彩的学术报告赢得了参会人员的阵阵掌声。

中国中药协会微循环用药专业委员会成立大会的圆满落幕,预示着中医药在微循环领域的研究与临床应用将进入规范化的发展阶段,同时有效整合了企业、医疗单位、科研机构、大专院校以及相关社会团体等各方资源,为广大医师建立了高水平的学术交流平台。与此同时,内容丰富、精彩纷呈的学术报告展示了我国冠脉微循环研究新进展与成果,也为今后微循环研究探索指明了道路,与会代表纷纷称赞,对我国微循环研究的快速发展具有极大的推动作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-10-25 lishizhe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-10-24 kcb069
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-23 cathymary
  7. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-21 易水河

    中医药在微循环领域的研究与临床应用将进入规范化的发展阶段

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1924737, encodeId=7ea71924e3714, content=<a href='/topic/show?id=3bf22244243' target=_blank style='color:#2F92EE;'>#中药协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22442, encryptionId=3bf22244243, topicName=中药协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Thu Jan 10 22:42:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718659, encodeId=476f1e1865963, content=<a href='/topic/show?id=58ee50609ee' target=_blank style='color:#2F92EE;'>#微循环#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50609, encryptionId=58ee50609ee, topicName=微循环)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b0832589054, createdName=smlt2019, createdTime=Mon Oct 29 20:42:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675584, encodeId=5c5b16e558439, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Thu Oct 25 14:42:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994804, encodeId=4b2c1994804a3, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Oct 24 20:42:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285577, encodeId=8d6312855e741, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409534, encodeId=2e1c140953441, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed May 23 01:42:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317237, encodeId=acbc31e2372e, content=中医药在微循环领域的研究与临床应用将进入规范化的发展阶段, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon May 21 14:47:07 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=317216, encodeId=5b4e31e216bc, content=中医药在改善冠状动脉微循环方面有其独到之处., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Mon May 21 11:17:20 CST 2018, time=2018-05-21, status=1, ipAttribution=)]
    2018-05-21 邓启付

    中医药在改善冠状动脉微循环方面有其独到之处.

    0